The ODYSSEY OUTCOMES trial is under way to judge the occurrence of MACE in a lot more than 18,000 patients with an acute coronary syndrome event 1 to a year before enrollment and LDL\C 70 mg/dL who receive alirocumab
The ODYSSEY OUTCOMES trial is under way to judge the occurrence of MACE in a lot more than 18,000 patients with an acute coronary syndrome event 1 to a year before enrollment and LDL\C 70…